The Wanfu combined antibody test detects antibodies to four major blood-borne infections, human immunodeficiency virus (HIV), hepatitis C virus (HCV), Treponema pallidum (syphilis) and hepatitis B virus (HBV), in a single workflow. Combined testing is valuable because these infections often overlap in the same at-risk populations and because undetected infection carries serious individual and public-health consequences. This article focuses on which populations benefit most from such screening.
Global guidance, including recommendations from the World Health Organization, stresses screening for HIV, syphilis and HBV during antenatal care so that mother-to-child transmission can be prevented and treatment started early. Blood donation programs screen all donated blood for these markers as a baseline safety measure. Beyond these groups, key populations, including men who have sex with men, people who inject drugs, sex workers and their partners, and people with multiple or untreated sexually transmitted infections, carry higher prevalence and warrant routine offer of testing. Anyone with unexplained liver dysfunction, prior exposure risk or a new pregnancy also fits the screening population. Syphilis in particular can cause severe congenital disease, which is why antenatal screening and treatment of the mother remain a core public-health intervention worldwide.
A single combined assay is efficient: one specimen yields four results, reducing patient burden, consumable use and turnaround time compared with four separate tests. For population screening to work, the test must be paired with pre- and post-test information, confirmatory testing for any reactive result, and a clear linkage to care and treatment. In antenatal and blood-bank settings the combined format supports high-throughput, repeatable workflows. Recording results in a single combined report also simplifies laboratory information systems and audit trails compared with managing four separate assays. The practical takeaway is that the who is defined by guidance and risk, while the combined format makes broad, repeated screening feasible.
Q: Which groups does WHO guidance emphasize for this screening? A: Antenatal attendees (for HIV, syphilis, HBV), blood donors, and key populations such as MSM, people who inject drugs, and sex workers and their partners.
Q: Why combine four infections in one test? A: These infections overlap in the same at-risk groups; one specimen yielding four results cuts burden, consumables and turnaround versus separate tests.
Q: Is a reactive antibody result conclusive? A: No. A reactive screening result should be followed by confirmatory testing and linkage to care, per standard screening practice.
The Wanfu combined antibody test detects antibodies to four major blood-borne infections, human immunodeficiency virus (HIV), hepatitis C virus (HCV), Treponema pallidum (syphilis) and hepatitis B virus (HBV), in a single workflow. Combined testing is valuable because these infections often overlap in the same at-risk populations and because undetected infection carries serious individual and public-health consequences. This article focuses on which populations benefit most from such screening.
Global guidance, including recommendations from the World Health Organization, stresses screening for HIV, syphilis and HBV during antenatal care so that mother-to-child transmission can be prevented and treatment started early. Blood donation programs screen all donated blood for these markers as a baseline safety measure. Beyond these groups, key populations, including men who have sex with men, people who inject drugs, sex workers and their partners, and people with multiple or untreated sexually transmitted infections, carry higher prevalence and warrant routine offer of testing. Anyone with unexplained liver dysfunction, prior exposure risk or a new pregnancy also fits the screening population. Syphilis in particular can cause severe congenital disease, which is why antenatal screening and treatment of the mother remain a core public-health intervention worldwide.
A single combined assay is efficient: one specimen yields four results, reducing patient burden, consumable use and turnaround time compared with four separate tests. For population screening to work, the test must be paired with pre- and post-test information, confirmatory testing for any reactive result, and a clear linkage to care and treatment. In antenatal and blood-bank settings the combined format supports high-throughput, repeatable workflows. Recording results in a single combined report also simplifies laboratory information systems and audit trails compared with managing four separate assays. The practical takeaway is that the who is defined by guidance and risk, while the combined format makes broad, repeated screening feasible.
Q: Which groups does WHO guidance emphasize for this screening? A: Antenatal attendees (for HIV, syphilis, HBV), blood donors, and key populations such as MSM, people who inject drugs, and sex workers and their partners.
Q: Why combine four infections in one test? A: These infections overlap in the same at-risk groups; one specimen yielding four results cuts burden, consumables and turnaround versus separate tests.
Q: Is a reactive antibody result conclusive? A: No. A reactive screening result should be followed by confirmatory testing and linkage to care, per standard screening practice.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
